Contemporary management of breast cancer in Nigeria: Insights from an institutional database.
Adult
Aged
Breast Neoplasms
/ metabolism
Databases, Factual
Disease Management
Drug Therapy
/ statistics & numerical data
Female
Humans
Mastectomy
/ statistics & numerical data
Middle Aged
Neoplasm Staging
Nigeria
Prospective Studies
Radiotherapy
/ statistics & numerical data
Receptor, ErbB-2
/ metabolism
Receptors, Estrogen
/ metabolism
Survival Analysis
Young Adult
breast
cancer
database
low- and middle-income country
survival
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 06 2021
15 06 2021
Historique:
revised:
01
12
2020
received:
13
07
2020
accepted:
04
01
2021
pubmed:
29
1
2021
medline:
8
9
2021
entrez:
28
1
2021
Statut:
ppublish
Résumé
High-quality data are needed to guide interventions aimed at improving breast cancer outcomes in sub-Saharan Africa. We present data from an institutional breast cancer database to create a framework for cancer policy and development in Nigeria. An institutional database was queried for consecutive patients diagnosed with breast cancer between January 2010 and December 2018. Sociodemographic, diagnostic, histopathologic, treatment and outcome variables were analyzed. Of 607 patients, there were 597 females with a mean age of 49.8 ± 12.2 years. Most patients presented with a palpable mass (97%) and advanced disease (80.2% ≥ Stage III). Immunohistochemistry was performed on 21.6% (131/607) of specimens. Forty percent were estrogen receptor positive, 32.8% were positive for HER-2 and 43.5% were triple negative. Surgery was performed on 49.9% (303/607) of patients, while 72% received chemotherapy and 7.9% had radiotherapy. At a median follow-up period of 20.5 months, the overall survival was 43.6% (95% CI -37.7 to 49.5). Among patients with resectable disease, 18.8% (57/303) experienced a recurrence. Survival was significantly better for early-stage disease (I and II) compared to late-stage disease (III or IV) (78.6% vs 33.3%, P < .001). Receipt of adjuvant radiotherapy after systemic chemotherapy was associated with improved survival in patients with locally advanced disease (68.5%, CI -46.3 to 86 vs 51%, CI 38.6 to 61.9, P < .001). This large cohort highlights the dual burden of advanced disease and inadequate access to comprehensive breast cancer care in Nigeria. There is a significant potential for improving outcomes by promoting early diagnosis and facilitating access to multimodality treatment.
Identifiants
pubmed: 33506499
doi: 10.1002/ijc.33484
pmc: PMC8394611
mid: NIHMS1732031
doi:
Substances chimiques
Receptors, Estrogen
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2906-2914Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2021 UICC.
Références
Int Q Community Health Educ. 2016 Jul;36(4):241-246
pubmed: 27389041
Eur J Cancer Care (Engl). 2019 Mar;28(2):e12986
pubmed: 30614109
Ann Afr Med. 2012 Jul-Sep;11(3):169-75
pubmed: 22684136
Radiother Oncol. 2014 May;111(2):321-6
pubmed: 24746579
World J Surg Oncol. 2018 Mar 22;16(1):63
pubmed: 29566711
Ann Surg Oncol. 2017 Mar;24(3):627-631
pubmed: 27743225
Breast. 2006 Jun;15(3):399-409
pubmed: 16085418
Cancer. 2020 May 15;126 Suppl 10:2379-2393
pubmed: 32348566
J Glob Oncol. 2017 Jan 25;3(5):490-496
pubmed: 29094087
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer. 2008 Oct 15;113(8 Suppl):2221-43
pubmed: 18816619
Cancer Epidemiol. 2018 Feb;52:120-127
pubmed: 29306221
Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):636-643
pubmed: 29678902
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
J Glob Oncol. 2019 May;5:1-6
pubmed: 31095453
Cancer Epidemiol. 2012 Oct;36(5):e271-8
pubmed: 22621842
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Int J Cancer. 2020 Mar 1;146(5):1208-1218
pubmed: 31087650
JAMA Oncol. 2018 Jun 1;4(6):765-766
pubmed: 29566116
Br J Surg. 1999 May;86(5):665-8
pubmed: 10361191
J Glob Oncol. 2017 Dec;3(6):765-772
pubmed: 29244986
Clin Transl Radiat Oncol. 2017 Jun 21;5:1-5
pubmed: 29594210